RxDoctor Payments Data

Kar Wong, MD

Clinical Cardiac Electrophysiology · Wynnewood, PANPI 1528059763

Payments from drug & device makers

$47,716in general payments, 2019–2025

Across 218 payments — averaging $218.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$44K
  • Medtronic$3K
  • Boston Scientific$342
  • Abbott$260
  • Johnson & Johnson$76
  • Kestra Medical Technology Services, Inc.$69
  • plus $80 from 4 others

What the payments were for

  • Speaking & faculty fees$52510%
  • Travel & lodging$1,89335%
  • Food & beverage$2,91454%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,716 in reported general payments places this provider in the 60th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$247,900
Medicare patients
2,695
Services billed
6,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban834$943,570
XareltoRivaroxaban467$512,903
JardianceEmpagliflozin86$95,840
EntrestoSacubitril/Valsartan88$82,144
Dofetilide195$53,334
FarxigaDapagliflozin Propanediol51$36,333
Metoprolol Succinate1,177$17,692
Flecainide Acetate326$12,853
VascepaIcosapent Ethyl26$11,526
Amiodarone Hcl363$11,409
Dabigatran EtexilateDabigatran Etexilate Mesylate37$9,132
Diltiazem 24hr Er (Cd)Diltiazem Hcl198$6,383
Atorvastatin Calcium422$4,458
Losartan Potassium338$3,372
Rosuvastatin Calcium85$2,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$76$512,903467 claims
Boehringer IngelheimJardiance$20$95,84086 claims
AstraZenecaFarxiga$12$36,33351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →